Expression of FAS/APO 1/CD 95 in thyroid tumors

Folia Histochemica et Cytobiologica

Volumn 45, Issue 2, 2007, Pages 87-91

  Rzeszutko, Marta ^a   Rzeszutko, Wojciech ^a   Dziegiel, Piotr ^a   Balcerzak, Waldemar ^a   Kaliszewski, Krzysztof ^a   Bolanowski, Marek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Apoptosis; Fas protein; Thyroid cancer

Indexed keywords

FAS ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PROTEIN DETERMINATION; PROTEIN FUNCTION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

EID: 34250683510     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Andrikoula M, Tsatsoulis A. The role of Fas-mediated apoptosis in thyroid disease. Eur J Pathol, 2001; 144: 561-568
2. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol, 1999; Metab 84: 4246-4252
3. Basola F, Fiore L, Baldanzi A, Giannini R, Dell'Omodarme M, Fontanini G, Pacini F, Danesi R, Miccoli P, Toniolo A. Suppression of Fas expression and down-regulation of Fas ligand in highly aggressive human thyroid carcinoma. Lab Invest, 2000; 80: 1413-1419
4. Dubská L, Matalova E, Míšek I. Detection of apoptosis in paraffin embedded tissues: the influence of tissue type and fixation. Acta Vet Brno, 2000; 71: 529-533
5. Grzelakowska-Sztabert B. Apoptosis and tumors. Post Biol Kom, 2000; 27: 9-43
6. Hidinger C, Williams ED, Sorbin LH. Histological typing of thyroid tumors. In: International histological classification of tumors. WHO [Eds] Springer, Berlin, 1998
7. Kam PCA, Ferch NI. Apoptosis: mechanisms and clinical implications. Anaesthesia, 2000; 55: 1081-1093
8. Kawakami A, Eguchi K. Involvement of apoptotic cell death in autoimmune diseases. Med Electron Microsc, 2002; 35: 1-8
9. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 1972; 26: 239-257
10. Koester SK, Bolton WE. The APO-1/Fas death signaling pathway: A life and death balance. Clin Immunol, 1998; 18: 97-102
11. Langlois NEI, Eremin O, Heys SD. Apoptosis and prognosis in cancer: rationale and relevance. J R Coll Surg Edinb, 2000; 45: 211-219
12. Maślińska D. Programmed cell death (apoptosis) in inflammatory process. Nowa Medycyna, 1999; 6: 6-10
13. Mezosi E, Yanazaki H, Bretz JD, Wang SH, Arscott P, Utsugi S, Gauger PG, Thompson NW, Baker JR. Aberrant apoptosis in thyroid epithelial cells from goiter nodules. J Clin Endocrin Metab, 2002; 87: 4264-4272
14. Mirakian R, Nye K, Palazzo F, Goode AW, Hammond LJ. Methods for detecting apoptosis in thyroid diseases. J Immunol Methods, 2002; 265: 161-175
15. Mitsiades C, Poulaki V, Fanourakis G, Sozopulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Hum Can Biol, 2006; 12: 3705-3712
16. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I. Thyroid carcinoma cells are resistant to Fas-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res, 2000; 60: 4122-4129
17. Osaki M, Kase S, Kodani I, Watanabe M, Adach H, Ito H. Expression of Fas and Fas ligand In human gastric adenomas and intestinal-type carcinoma: correlation with proliferation and apoptosis. Gastric Cancer, 2001; 4: 198- 205
18. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas) - mediated apoptosis. Curr Opin Immunol, 1998; 10: 545- 551
19. Ramp U, Bretschneider U, Ebert T, Karagiannidis C, Willers R, Gabbert HE, Gerharz CD. Prognostic implications of CD95 receptor expression in clear cell renal carcinomas. Hum Pathol, 2003; 34: 174-179
20. Reed JC. Mechanisms of apoptosis. Am J Pathol, 2000; 157: 1415-1430
21. Saikumar P, Dong Z, Mikhailov V, Denton M, Weiberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms and relevance to disease. Am J Med, 1999; 107: 489-506
22. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD 95 and its ligand. Pharmacol Therapeut, 2000; 88: 333-347
23. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res, 1999; 5: 2464-2469
24. Takehara T. Fas and Fas ligand in human hepatocellular carcinoma. J Gastroenterol, 2001; 36: 727-728
25. Wajant H, Pfizenmaier K, Scheurich P. Survey non-apoptotic Fas signaling. Cytokine Growth Factor Rev, 2003; 14: 53-66
26. Yoshida A, Nakamura Y, Imada T, Asaga T, Shimizu A, Harada M. Apoptosis and proliferative activity In thyroid tumors. Jpn J Surg, 1999; 29: 204-208